Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer Research

• Publication date

  2012-11-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/0008-5472.CAN-12-2753PMID 23118055PMCID PMC3528345
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1

  2012cited by this paper
• Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

  2012cited by this paper
• Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

  2012cited by this paper
• PARP-1 Activation—Bringing the Pieces Together

  2012cited by this paper
• Advances in using PARP inhibitors to treat cancer

  2012cited by this paper
• DNA Damage and Cellular Stress Responses Increased PARP-1 Association with DNA in Alkylation Damaged , PARP-Inhibited Mouse Fibroblasts

  2012cited by this paper
• Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53

  2012cited by this paper
• Roles of sequential ubiquitination of PCNA in DNA‐damage tolerance

  2011cited by this paper
• Dynamic regulation of PCNA ubiquitylation/deubiquitylation

  2011cited by this paper
• Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

  2011cited by this paper
• Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells

  2011cited by this paper
• Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

  2011cited by this paper
• The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

  2011cited by this paper
• Competition between PARP-1 and Ku70 control the decision between high-fidelity and mutagenic DNA repair.

  2011cited by this paper
• Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes*

  2011cited by this paper
• Poly(ADP-ribose) polymerase and XPF–ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells

  2011cited by this paper
• PARP inhibition: PARP1 and beyond

  2010cited by this paper
• The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets.

  2010cited by this paper
• Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate

  2010cited by this paper
• Susceptibility pathways in Fanconi's anemia and breast cancer.

  2010cited by this paper
• Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks.

  2010cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• PARP1-dependent Kinetics of Recruitment of MRE11 and NBS1 Proteins to Multiple DNA Damage Sites*

  2008cited by this paper
• The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases.

  2008cited by this paper
• Targeted therapy for cancer using PARP inhibitors.

  2008cited by this paper
• Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells

  2007cited by this paper
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

  2006cited by this paper
• Depicting combinatorial complexity with the molecular interaction map notation

  2006cited by this paper
• Poly(ADP-ribose): novel functions for an old molecule

  2006cited by this paper
• Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis

  2006cited by this paper
• Parp‐1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells

  2006cited by this paper
• Poly(ADP-ribose) Polymerase Activity Prevents Signaling Pathways for Cell Cycle Arrest after DNA Methylating Agent Exposure*

  2005cited by this paper
• Spontaneous Homologous Recombination Is Induced by Collapsed Replication Forks That Are Caused by Endogenous DNA Single-Strand Breaks

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Similar Effects of Brca2 Truncation and Rad51 Paralog Deficiency on Immunoglobulin V Gene Diversification in DT40 Cells Support an Early Role for Rad51 Paralogs in Homologous Recombination

  2005cited by this paper
• Involvement of Poly(ADP-ribose) Polymerase-1 and XRCC1/DNA Ligase III in an Alternative Route for DNA Double-strand Breaks Rejoining*

  2004cited by this paper
• Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse

  2003cited by this paper
• A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage.

  2003cited by this paper
• Poly(ADP-ribose) Polymerase-2 (PARP-2) Is Required for Efficient Base Excision DNA Repair in Association with PARP-1 and XRCC1*

  2002cited by this paper
• RAD18 and RAD54 cooperatively contribute to maintenance of genomic stability in vertebrate cells

  2002cited by this paper
• Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5′-Phosphorylated DNA Double-Strand Breaks by Replication Runoff

  2000cited by this paper
• PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase*

  1999cited by this paper
• Quality control by DNA repair.

  1999cited by this paper
• XRCC1 Is Specifically Associated with Poly(ADP-Ribose) Polymerase and Negatively Regulates Its Activity following DNA Damage

  1998cited by this paper
• Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks.

  1995cited by this paper
• Role of poly(ADP-ribose) formation in DNA repair

  1992cited by this paper
• ADP-ribosylation in mammalian cell ghosts. Dependence of poly(ADP-ribose) synthesis on strand breakage in DNA.

  1980cited by this paper
• (ADP-ribose)n participates in DNA excision repair

  1980cited by this paper
• Poly(ADP-ribose) levels in carcinogen-treated cells

  1979cited by this paper

• PARP1 and PARP2 are dispensable for DNA repair by microhomology-mediated end-joining at double-ended DSBs

  2026cites this paper
• Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study

  2026cites this paper
• PARP inhibitors induce a senescence phenotype in non-small cell lung carcinoma cell lines.

  2026cites this paper
• PARP1 Suppression Drives ROS Resistance in Aneuploid Cancer Cells

  2026cites this paper
• A SERS-based biosensor for optical monitoring of PARP1 trapping dynamics and high-throughput screening of modulators.

  2026cites this paper
• The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

  2026cites this paper
• Metformin Sensitizes PTEN-deficient Prostate Cancer to PARP Inhibitors by Rebuilding NADP+ Homeostasis

  2026cites this paper
• Discovery of selective PARP1/CDK6 dual target inhibitors modulating Wnt signaling pathway for the treatment of TNBC.

  2026cites this paper
• Targeting ZDHHC12-mediated PARP1 palmitoylation potentiates PARP inhibitor cytotoxicity.

  2026cites this paper
• An organolutetium nanosensitizer synergizes with PARP inhibition to unleash STING-mediated immunity for low-dose radioimmunotherapy

  2026cites this paper
• Long-term exposure to the ethanol-derived metabolite acetaldehyde elevates structural genomic alterations but not base substitutions

  2026cites this paper
• Cellular strategies for repairing trapped protein-DNA complexes.

  2026cites this paper
• Fork Reversal Safeguards Epigenetic Inheritance During Replication Stress

  2026cites this paper
• Impairment of oxidative metabolism compromises Rad51 recruitment and potentiates PARP inhibitor effectiveness in ovarian cancer

  2026cites this paper
• Harnessing DNA polymerase beta defect enhances synthetic lethality and treatment response in gastric cancer cells: implication for immunotherapy

  2026cites this paper
• Multi-omics integrative analysis of stemness-associated pathological signatures to guide prognosis and therapeutic strategies in uveal melanoma.

  2026cites this paper
• The PARG frontier: mechanisms of PAR turnover and opportunities in precision oncology.

  2026cites this paper
• Synthesis and evaluation of boron-containing heterocycles as drug candidates: Benzoxazaborinins as PARP inhibitors

  2026cites this paper
• Synergistic Cellular Toxicity from Inhibition of Poly(ADP-ribose) Glycohydrolase (PARG) and Ubiquitin-Specific Protease 1 (USP1).

  2026cites this paper
• Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination–proficient prostate cancer

  2026cites this paper
• PARP inhibition generates enhanced CD8+ central memory T cells by transcriptional and metabolic reprogramming

  2026influential citation
• Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast Cancer.

  2026cites this paper
• Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids

  2026cites this paper
• Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis

  2026cites this paper
• Zero-shot biological reasoning with open-weights large language models reproduces CRISPR screen based prediction of synthetic lethal interactions

  2026cites this paper
• Roles of base and nucleotide excision repair activities in cancer treatment: implications for prognosis and resistance to therapy in breast and colorectal cancers.

  2026cites this paper
• Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation.

  2026cites this paper
• Z-Guggulsterone Inhibits Triple-Negative Breast Cancer Progression by Blocking Autophagosome-Lysosome Fusion via OGT-Mediated SNAP29 O-GlcNAcylation.

  2026cites this paper
• A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture

  2026cites this paper
• Novel therapeutic potential of the PARP inhibitor talazoparib in synovial sarcoma and its combined effect with ATR inhibitor

  2026cites this paper
• PARP inhibitors potentiate proton therapy end-of-range effects by accelerating replication forks and promoting transcription conflict.

  2025cites this paper
• Mass spectrometry-based proteomics in glioblastoma - current understanding and future impact.

  2025cites this paper
• Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• Rewiring DNA repair with PARP-based chemical inducers of proximity

  2025cites this paper
• Multi-omics Characterization of Acquired Olaparib Resistance in BRCA1 and BRCA2 Mutant Breast Cancer Cell Lines

  2025cites this paper
• PARP inhibitors in melanoma treatment: potential, challenges, and future directions

  2025cites this paper
• R2eGIN: Residual Reconstruction Enhanced Graph Isomorphism Network for Accurate Prediction of Poly (ADP–Ribose) Polymerase Inhibitors

  2025cites this paper
• Research Progress on the Combination of PARP Inhibitors (PARPi) and Immune Checkpoint Inhibitors (ICIs)

  2025cites this paper
• Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging

  2025cites this paper
• The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models

  2025cites this paper
• USP37 counteracts HLTF to protect damaged replication forks and promote survival of BRCA1-deficient cells and PARP inhibitor resistance

  2025cites this paper
• Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer

  2025cites this paper
• PARPs and ADP-ribosyl hydrolases in cancer therapy: From drug targets to biomarkers.

  2025cites this paper
• Bibliometric analysis of global research trends in pancreatic cancer immunotherapy

  2025cites this paper
• Chrysin sensitizes glioblastoma cells and spheroids to temozolomide treatment by reducing EMT and stemness phenotypes, as well as targeting multidrug resistance proteins

  2025cites this paper
• SUMOylation-regulated genes in colon cancer: expression patterns and clinical implications

  2025cites this paper
• PARP inhibitor augments anti-tumor efficacy of DNMT inhibitor by inducing senescence in cholangiocarcinoma

  2025cites this paper
• Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Combination with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis

  2025cites this paper
• PARP1 regulates establishment of the ovarian reserve and age at natural menopause

  2025cites this paper
• Discovery and Pharmacological Evaluation of Potent and Highly Selective PARP1 Inhibitors.

  2025cites this paper
• Expanding PARP Inhibitor Use in Prostate Cancer Beyond DNA Repair Defects.

  2025cites this paper
• PALB2 deficiency may sensitize H3K27M-mutant pediatric HGG cells to BMN673/talazoparib

  2025cites this paper
• Poly(ADP-ribose) polymerase-1 (PARP1)-based dual inhibitors targeting cancer synthetic lethality (2022-present): advances and perspectives.

  2025cites this paper
• Asymmetrical recognition and processing of double-strand breaks formed during DNA replication

  2025cites this paper
• Disrupting the Base Excision Repair (BER) Pathway by Targeting the Abasic Site Enhances the Sensitivity of PARP Inhibitor in HR-Proficient Cancer Cells.

  2025cites this paper
• Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors

  2025cites this paper
• Multiple functions of BRD4 in maintaining genomic stability in cancers.

  2025cites this paper
• Arginine methylation regulates Ewing sarcoma cell viability in a EWSR1::FLI1 dependent manner and provides a therapeutic opportunity

  2025cites this paper
• NASP modulates histone turnover to drive PARP inhibitor resistance

  2025cites this paper
• Homologous Repair‐Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy

  2025cites this paper
• DNA damage response inhibitors in cancer therapy: Mechanisms, clinical development, and combination strategies.

  2025cites this paper
• High-throughput evaluation of novel WRN inhibitors.

  2025cites this paper
• Combining STING Agonists with PARP Inhibitors Mounts an NK-Dependent Defense against Therapy-Resistant Breast Cancer.

  2025cites this paper
• PROTACs improve selectivity for targeted proteins

  2025influential citation
• Targeting base excision repair in precision oncology.

  2025cites this paper
• Targeting DNA damage sensors for cancer therapy.

  2025cites this paper
• A Phase II Multi-Center Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma.

  2025cites this paper
• Peripheral Neuropathy in Patients With Ovarian Cancer Administrating Poly ADP-Ribose Polymerase Inhibitors: A Real-World Study Based on Bayesian Disproportionality Analysis of the US Food and Drug Administration Adverse Event Reporting System.

  2025cites this paper
• Population Pharmacokinetic Modeling of Total and Unbound Pamiparib in Glioblastoma Patients: Insights into Drug Disposition and Dosing Optimization

  2025cites this paper
• PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapy.

  2025cites this paper
• PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced

  2025influential citation
• Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy

  2025cites this paper
• Assessing PARP trapping dynamics in ovarian cancer using a CRISPR-engineered FRET biosensor

  2025cites this paper
• BRCA2 prevents PARPi-mediated PARP1 retention to protect RAD51 filaments

  2025cites this paper
• Synergistic enhancement of PARP inhibition via small molecule UNI66-mediated suppression of BRD4-dependent transcription of RAD51 and CtIP

  2025cites this paper
• DNA repair and the contribution to chemotherapy resistance

  2025cites this paper
• Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.

  2025cites this paper
• The Landscape of PARP Inhibitors in Solid Cancers

  2025cites this paper
• The Combination of PARP and Topoisomerase 1 Inhibitors Improves Radiation Therapy for Ewing Sarcoma

  2025cites this paper
• Empowering PARP inhibition through rational combination: Mechanisms of PARP inhibitors and combinations with a focus on the treatment of metastatic castration-resistant prostate cancer.

  2025cites this paper
• Genome-wide CRISPR activation screen identifies ARL11 as a sensitivity determinant of PARP inhibitor therapy

  2025cites this paper
• Homologous recombination deficiency: a reliable biomarker or a misleading indicator?

  2025cites this paper
• Current and future therapies for small cell lung carcinoma

  2025cites this paper
• The Poly (ADP-Ribose) Polymerase-1 Enzyme Is Overexpressed in Various Solid Canine Tumours: An Immunohistochemical Study.

  2025cites this paper
• DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition.

  2025cites this paper
• Chemical inhibition of RPA gap protection sensitizes BRCA1-deficient cancers to PARP inhibition

  2025cites this paper
• The deubiquitination-PARylation positive feedback loop of the USP10-PARP1 axis promotes DNA damage repair and affects therapeutic efficacy of PARP1 inhibitor

  2025cites this paper
• PARP inhibitors elicit a cellular senescence mediated inflammatory response in homologous recombination proficient cancer cells

  2025cites this paper
• Joining of DNA breaks- interplay between DNA ligases and poly (ADP-ribose) polymerases.

  2025cites this paper
• Effects of a Cancer-Associated Mutation and Multiple Serine Phosphorylation on Poly(ADP-Ribose) Polymerase 2

  2025cites this paper
• Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer

  2025cites this paper
• BRCA1 and BRCA2 in DNA damage and replication stress response: Insights into their functions, mechanisms, and implications for cancer treatment.

  2025cites this paper
• Parp1 deletion rescues cerebellar hypotrophy in xrcc1 mutant zebrafish

  2025cites this paper
• Safety and potential radiosensitizing effect of Olaparib in combination with breast radiotherapy for TNBC patients with residual disease: long-term results from the RADIOPARP Phase I Trial: Safety and Radiosensitization of Olaparib with Radiotherapy in TNBC.

  2025cites this paper
• PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer

  2025cites this paper
• PARP1 and PARP2 are dispensable for DNA repair by microhomology-mediated end-joining during mitosis

  2025cites this paper
• Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors

  2025influential citation
• Deciphering molecular pathways in urological cancers: a gateway to precision therapeutics.

  2025cites this paper
• Tumour Cell Size Control and Its Impact on Tumour Cell Function

  2025cites this paper
• Druggable Molecular Networks in BRCA1/BRCA2-Mutated Breast Cancer

  2025cites this paper